Bridge Biotherapeutics

Bridge Biotherapeutics

Biotechnology, Milestone CTR Dr Ste 600, Seongnam-si, , 20876, Maryland, 12410, United States, 11-50 Employees

bridgebiorx.com

  • facebook
  • twitter
  • LinkedIn

Who is BRIDGE BIOTHERAPEUTICS

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the d...

Read More

map
  • 12410 Milestone CTR Dr Ste 600, Seongnam-si, Maryland, 20876, United States Headquarters: 12410 Milestone CTR Dr Ste 600, Seongnam-si, Maryland, 20876, United States
  • 2015 Date Founded: 2015
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

checked-icon Does something look wrong? Fix it. | View contact records from BRIDGE BIOTHERAPEUTICS

Bridge Biotherapeutics Org Chart and Mapping

Employees

Toan Nguyen

Director Computational Chemistry and Informatics

Yong-Hee Lee

SVP, Head of Development

Jehrod Brenneman

Vice President, Head of Discovery Chemical Sciences

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Bridge Biotherapeutics

Answer: Bridge Biotherapeutics's headquarters are located at Milestone CTR Dr Ste 600, Seongnam-si, , 20876, Maryland, 12410, United States

Answer: Bridge Biotherapeutics's official website is https://bridgebiorx.com

Answer: Bridge Biotherapeutics's revenue is $1 Million to $5 Million

Answer: Bridge Biotherapeutics has 11-50 employees

Answer: Bridge Biotherapeutics is in Biotechnology

Answer: Bridge Biotherapeutics contact info: Phone number: Website: https://bridgebiorx.com

Answer: Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access